SCHEMBL6288381

SCHEMBL6288381

Cc1ccc(-c2nc(-n3cncn3)c3c(C)nc(C)n3n2)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.34
GSK3B P49841 1/20 0.33
TP53 P04637 3/20 0.32
SMN1; SMN2 Q16637 3/20 0.32
RXFP1 Q9HBX9 1/20 0.32
MEN1 O00255 4/20 0.32
KMT2A Q03164 4/20 0.32
ALDH1A1 P00352 3/20 0.32
CYP2C19 P33261 3/20 0.32
MAPT P10636 2/20 0.32
KDM4E B2RXH2 1/20 0.32
TSHR P16473 1/20 0.32
AHR P35869 1/20 0.32
XDH P47989 1/20 0.31
CYP1A2 P05177 2/20 0.31
CYP2C9 P11712 2/20 0.31
CYP3A4 P08684 1/20 0.31
ADORA2A P29274 1/20 0.31
ADORA1 P30542 1/20 0.31
CA12 O43570 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5620144 0.90 AHR (0.36) LMNAGSK3BALDH1A1MAPTKDM4E
SCHEMBL6288657 0.88 SMN1; SMN2 (0.42) TP53SMN1; SMN2KMT2AALDH1A1MAPT
SCHEMBL6291360 0.86 LMNA (0.32) LMNATP53SMN1; SMN2RXFP1MEN1
SCHEMBL8361756 0.86 ALOX5AP (0.36) GSK3BALDH1A1KDM4EKCNJ5KCNJ3
SCHEMBL8361757 0.85 CYP11B2 (0.32) GSK3BADORA2AADORA1KCNJ5KCNJ3
SCHEMBL5916362 0.84 KCNJ5 (0.35) GSK3BSMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL6288587 0.84 GRM7 (0.44) LMNATP53SMN1; SMN2MAPTNPC1
SCHEMBL8361755 0.83 ALDH1A1 (0.45) LMNAGSK3BTP53SMN1; SMN2MEN1
SCHEMBL6291873 0.83 MAPT (0.31) LMNATP53ALDH1A1MAPTADORA2A
SCHEMBL5916392 0.82 PDE2A (0.36) GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6936609-B2 Imidazotriazines for use as phosphodiesterase inhibitors BAYER HEALTHCARE AG (DE) 2005-08-30 US disclosed
US-20040249148-A1 Imidazotriazines for use as phosphodiesterase inhibitors BAYER HEALTHCARE AG (DE) 2004-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040249148-A1 Imidazotriazines for use as phosphodiesterase inhibitors PDE3A, PDE2A, PDE4A LMNA 2027/4885GSK3B 2100/4885TP53 4455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.